Anti-hypertensive drug utilization in Continental Portugal (1999-2004);Utilização de medicamentos anti-hipertensivos em Portugal Continental 1999-2004

Revista Portuguesa de Cardiologia

Volumn 25, Issue 3, 2006, Pages 273-292

  Furtado, Cláudia ^a   Pinto, Miguel ^a  

^a Inst Nac Farmacia Medicamento   (Portugal)

Author keywords

Antihypertensive agents; Drug utilization; Pharmacoepidemiology

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN; NIFEDIPINE; RAMIPRIL;

AMBULATORY CARE; ARTICLE; DENMARK; DRUG COST; DRUG UTILIZATION; HYPERTENSION; NATIONAL HEALTH SERVICE; NORWAY; PORTUGAL; PRESCRIPTION; SWEDEN; TREND STUDY; UNITED KINGDOM;

ANTIHYPERTENSIVE AGENTS; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; EUROPE; HUMANS; PORTUGAL;

EID: 33744495364     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Padwal R., SE, McAlister, FA. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. British Medical Journal 2001;32:977-80.
2. Graça MJ, Lino A, Dias CM et al. Inquérito Nacional de Saúde - DADOS GERAIS - Continente 1998-1999. Observatório Nacional de Saúde.
3. Macedo E (coord.). Estudo da Prevalência, Conhecimento, Tratamento e Controlo da Hipertensão em Portugal. Instituto de Biologia Molecular e Celular e Faculdade de Medicina da Universidade do Porto 2004.
4. António A, Faria Vaz. A. Observatório do Medicamento e Produtos de Saúde. Evolução da utilização de anti hipertensores em Portugal de 1995 a 2001. Instituto da Farmácia e do Medicamento. 2003. Available online at http://www.infarmed.pt/pt/observatorio/ ficheiros/rel_anti_hipertensores.pdf
5. Figueiras A, Caamaño F, Gestal Otero J. Metodologia de los estudios de utilización de medicamentos en atención primaria. Gaceta Sanitaria 2000;14(supl)3:7-19.
6. Juanes VG, Villar MA, González S F et al. Análisis del consume de medicamentos utilizando indicadores de calidad en la prescripción. Atención Primaria 2000;9(25):46-60.
7. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical (ATC) classification index including defined daily doses (DDD) for plain substances. Available online at http://www.whocc.no/atcddd/
8. EURO MED STAT. The Library of European Union Pharmaceutical Indicators. Available online at http://www.euromedstat.cnr.it/pdf/utilisation%2004-07-30.pdf
9. Nordic Medico Statistical Committee. Medicines Consumption in the Nordic Countries 1999-2003. Nordic Medico Statistical Committee 2004. Available online at http://www.nomnos.dk/Medicinebook/medicines%20consumption.pdf
10. Health and Social Care Information Centre. Prescription Cost Analysis: England 2004. Department of Health 2005. Available online at http://www.dh.gov.uk/assetRoot/04/10/76/26/04107626.pdf
11. Direcção Geral de Saúde. Centres de Saùde e Hospitals - Recursos e Produção do SNS - 2003. Direcçã o Geral de Saúde - Ministério da Saúde. Available online at http://www.dgsaude.pt/upload/membro.id/ficheiros/i006792.pdf
12. Garcia del Pozo J, Ramos Sevillano E, Abajo FJ, Mateos Campos R. Utilización de anti hipertensivos en España (1995-2001). Revista Española de Cardiologia 2004;57(3): 241-9.
13. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43(1):10-7.
14. Prieto M, de Abajo FJ, Montero D, Martin-Serrano G, Madurga M, Palop R. Uso de antihipertensivos en España 1985-1995. Medicina Clinica 1998;110:247-253.
15. Prescription Pricing Authority - CARDIOVASCULAR PRESCRIBING 2004. Available online at http://www.ppa.org.uk/news/pact-052004.htm Accessed in December 2004.
16. Osservatorio Nazionale sull'impiego dei medicinali. L'uso dei Farmaci in Italia. Rapporta nazionale anno 2003. Ministero della Salute. Available online at http://www.ministerosalute.it/medicinali/resources/documenti/osmed/rapporti/ osmed_2003.pdf
17. Agence Française de sécurité sanitaire des produits de santé. Analyse des ventes de médicaments aux officines et aux hôpitaux en France 1992-2002. 4ème édition. 2004. Available online at http://agmed.sante.gouv.fr
18. Prescription Pricing Authority. Cardiovascular Disease - Prescribing Guidance and Discussion Points. Available online at http://www.ppa.org.uk/ systems/pctreports/pctreport_20034.pdf
19. Denig P, Haaijer-Ruskamp FM. Therapeutic decision making of physicians. Pharm Weekbl Sci 1992;14(1):9-15.
20. Wahlstrom R, Hummers-Pradier E, Lundborg CS et al. Drug Education Project Group. Variations in asthma treatment in five European countries - judgement analysis of case simulations. Family Practice 2002;19(5):452-60.
21. Pittrow D, Kirch W, Bramlage P, et al. Patterns of antihypertensive drug utilization in primary care. European Journal of Clinical Pharmacology 2004;60:135-142.
22. Jabary NS, Herrero AM, Gonzalez JA. The use of antihypertensive therapy in Spain (1986-1994). American Journal of Hypertension 2000;13(6):607-10.
23. Dickson M, Jacobzone S. OECD Health Working Papers no.1 - Pharmaceutical use and expenditure for cardiovascular disease and stroke: a study of 12 OECD countries. February 2003.
24. Chobanian AV, Bakris GL, Black HR. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003;289:2560-2572.
25. European Society of Hypertension, European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003;21:1011-1053.
26. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension 2003;21(11):1983-92.
27. National Institute of Clinical Excellence. Hypertension - Management of hypertension in adults in primary care. Clinical Guideline 18, 2004. Available online at http://www.nice.org.uk/pdf/CG018NICEguideline.pdf
28. Direcção Geral de Saúde. Normas para o Diagnóstico, Tratamento e Controlo da Hipertensão Arterial. Direcção Geral de Saúde, Ministério da Saúde 2004.
29. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
30. Task Force Members, López-Sendón J, Swedberg K, McMurray J et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease: The Task Force on ACE-inhibitors of the European Society of Cardiology European Heart Journal 2004;25:1454-1470.
31. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. New England Journal of Medicine 1993;329:1456-1462.
32. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine 2000;342(3):145-53.
33. Greving JP, Denig P, van der Veen WJ et al. Does comorbidity explain trends in prescribing of newer anti hypertensive agents? Journal of Hypertension 2004;22(11):2209-2215.
34. UK Medicines Information. Therapeutic Class Summaries - Evaluated Information for the NHS - Angiotensin 2 Receptor Antagonists. National Health Service 2003. Available online at http://www.ukmi.nhs.uk/
35. Fischer MA, Avorn J. Economic Implications of Evidence Based Prescribing for Hypertension. JAMA 2004;2991(15): 1850-1856.
36. Wathen B, Dean T. An evaluation of the impact of NICE guidance on GP prescribing. British Journal of General Practice 2004;54(499):103-7.